Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1990 Sep 1;172(3):1001–1004. doi: 10.1084/jem.172.3.1001

Immunological crossreactivity between the human immunodeficiency virus type 1 virion infectivity factor and a 170-kD surface antigen of Schistosoma mansoni

PMCID: PMC2188553  PMID: 1696953

Abstract

A monoclonal antibody (mAb) directed against a synthetic peptide derived from the sequence of the human immunodeficiency virus type 1 (HIV-1) regulatory protein virion infectivity factor (vif) labeled the surface of Schistosoma mansoni schistosomula by indirect immunofluorescence. Western blotting showed that two S. mansoni proteins of 170 and 65 kD were recognized by the mAb. Sera from 20% of S. mansoni-infected HIV-seronegative individuals tested recognized the PS4 peptide in an ELISA as did sera from S. mansoni-infected rats. Sera from individuals seropositive for HIV-1, but without schistosomiasis, that reacted with the vif peptide also recognized a 170-kD S. mansoni protein. This crossreactive S. mansoni antigen appears to be a target of immunity in vivo since passive transfer of the mAb VIF-CD3 to naive rats had a protective effect against a challenge infection with S. mansoni cercariae.

Full Text

The Full Text of this article is available as a PDF (376.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ameisen J. C., Guy B., Chamaret S., Loche M., Mouton Y., Neyrinck J. L., Khalife J., Leprevost C., Beaucaire G., Boutillon C. Antibodies to the nef protein and to nef peptides in HIV-1-infected seronegative individuals. AIDS Res Hum Retroviruses. 1989 Jun;5(3):279–291. doi: 10.1089/aid.1989.5.279. [DOI] [PubMed] [Google Scholar]
  2. Biggar R. J., Gigase P. L., Melbye M., Kestens L., Sarin P. S., Bodner A. J., Demedts P., Stevens W. J., Paluku L., Delacollette C. ELISA HTLV retrovirus antibody reactivity associated with malaria and immune complexes in healthy Africans. Lancet. 1985 Sep 7;2(8454):520–523. doi: 10.1016/s0140-6736(85)90461-1. [DOI] [PubMed] [Google Scholar]
  3. Biggar R. J., Johnson B. K., Oster C., Sarin P. S., Ocheng D., Tukei P., Nsanze H., Alexander S., Bodner A. J., Siongok T. A. Regional variation in prevalence of antibody against human T-lymphotropic virus types I and III in Kenya, East Africa. Int J Cancer. 1985 Jun 15;35(6):763–767. doi: 10.1002/ijc.2910350611. [DOI] [PubMed] [Google Scholar]
  4. Butterworth A. E., Capron M., Cordingley J. S., Dalton P. R., Dunne D. W., Kariuki H. C., Kimani G., Koech D., Mugambi M., Ouma J. H. Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses. Trans R Soc Trop Med Hyg. 1985;79(3):393–408. doi: 10.1016/0035-9203(85)90391-8. [DOI] [PubMed] [Google Scholar]
  5. Butterworth A. E., Dalton P. R., Dunne D. W., Mugambi M., Ouma J. H., Richardson B. A., Siongok T. K., Sturrock R. F. Immunity after treatment of human schistosomiasis mansoni. I. Study design, pretreatment observations and the results of treatment. Trans R Soc Trop Med Hyg. 1984;78(1):108–123. doi: 10.1016/0035-9203(84)90190-1. [DOI] [PubMed] [Google Scholar]
  6. Clegg J. A., Smithers S. R. The effects of immune rhesus monkey serum on schistosomula of Schistosoma mansoni during cultivation in vitro. Int J Parasitol. 1972 Mar;2(1):79–98. doi: 10.1016/0020-7519(72)90036-7. [DOI] [PubMed] [Google Scholar]
  7. Grzych J. M., Capron M., Bazin H., Capron A. In vitro and in vivo effector function of rat IgG2a monoclonal anti-S. mansoni antibodies. J Immunol. 1982 Dec;129(6):2739–2743. [PubMed] [Google Scholar]
  8. Guy B., Kieny M. P., Riviere Y., Le Peuch C., Dott K., Girard M., Montagnier L., Lecocq J. P. HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature. 1987 Nov 19;330(6145):266–269. doi: 10.1038/330266a0. [DOI] [PubMed] [Google Scholar]
  9. Khalife J., Capron M., Capron A., Grzych J. M., Butterworth A. E., Dunne D. W., Ouma J. H. Immunity in human schistosomiasis mansoni. Regulation of protective immune mechanisms by IgM blocking antibodies. J Exp Med. 1986 Nov 1;164(5):1626–1640. doi: 10.1084/jem.164.5.1626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Khalife J., Dunne D. W., Richardson B. A., Mazza G., Thorne K. J., Capron A., Butterworth A. E. Functional role of human IgG subclasses in eosinophil-mediated killing of schistosomula of Schistosoma mansoni. J Immunol. 1989 Jun 15;142(12):4422–4427. [PubMed] [Google Scholar]
  11. Khalife J., Guy B., Capron M., Kieny M. P., Ameisen J. C., Montagnier L., Lecocq J. P., Capron A. Isotypic restriction of the antibody response to human immunodeficiency virus. AIDS Res Hum Retroviruses. 1988 Feb;4(1):3–9. doi: 10.1089/aid.1988.4.3. [DOI] [PubMed] [Google Scholar]
  12. Smithers S. R., Terry R. J. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology. 1965 Nov;55(4):695–700. doi: 10.1017/s0031182000086248. [DOI] [PubMed] [Google Scholar]
  13. Sodroski J., Goh W. C., Rosen C., Tartar A., Portetelle D., Burny A., Haseltine W. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science. 1986 Mar 28;231(4745):1549–1553. doi: 10.1126/science.3006244. [DOI] [PubMed] [Google Scholar]
  14. de Lima e Costa M. F., Proietti F. A., Paulino U. H., Antunes C. M., Guimarães M. D., Rocha R. S., Katz N. Absence of cross-reactivity between Schistosoma mansoni infection and human immunodeficiency virus (HIV). Trans R Soc Trop Med Hyg. 1988;82(2):262–262. doi: 10.1016/0035-9203(88)90441-5. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES